Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review

References

• ChongHYTeohSLWuDBKotirumSChiouCFChaiyakunaprukNGlobal economic burden of schizophrenia: a systematic reviewNeuropsychiatr Dis Treat20161235737326937191
   PubMed Web of Science ®Google Scholar
• AndreasenNCCarpenterWTJrKaneJMLasserRAMarderSRWeinbergerDRRemission in schizophrenia: proposed criteria and rationale for consensusAm J Psychiatry2005162344144915741458
   PubMed Web of Science ®Google Scholar
• EmsleyRChilizaBAsmalLThe evidence for illness progression after relapse in schizophreniaSchizophr Res20131481–311712123756298
   PubMed Web of Science ®Google Scholar
• WunderinkLNieboerRMWiersmaDSytemaSNienhuisFJRecovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trialJAMA Psychiatry201370991392023824214
   PubMed Web of Science ®Google Scholar
• LeuchtSTardyMKomossaKAntipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysisLancet201237998312063207122560607
   PubMed Web of Science ®Google Scholar
• ZipurskyRBMenezesNMStreinerDLRisk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic reviewSchizophr Res20141522–340841423972821
   PubMed Web of Science ®Google Scholar
• JiangYNiWEstimating the impact of adherence to and persistence with atypical antipsychotic therapy on health care costs and risk of hospitalizationPharmacotherapy201535981382226406773
   PubMed Web of Science ®Google Scholar
• EmsleyRChilizaBAsmalLHarveyBHThe nature of relapse in schizophreniaBMC Psychiatry2013135023394123
   PubMed Web of Science ®Google Scholar
• OwenMJO’DonovanMCSchizophrenia and the neurodevelopmental continuum: evidence from genomicsWorld Psychiatry201716322723528941101
   PubMed Web of Science ®Google Scholar
• McGlashanTHIs active psychosis neurotoxic?Schizophr Bull200632460961316914639
   PubMed Web of Science ®Google Scholar
• MorganCLappinJHeslinMReappraising the long-term course and outcome of psychotic disorders: the AESOP-10 studyPsychol Med201444132713272625066181
   PubMed Web of Science ®Google Scholar
• LiebermanJJodyDGeislerSTime course and biologic correlates of treatment response in first-episode schizophreniaArch Gen Psychiatry19935053693768098203
   PubMed Web of Science ®Google Scholar
• EmsleyRRabinowitzJMedoriRRemission in early psychosis: rates, predictors, and clinical and functional outcome correlatesSchizophr Res2007891–312913917095194
   PubMed Web of Science ®Google Scholar
• RobinsonDWoernerMGAlvirJMPredictors of relapse following response from a first episode of schizophrenia or schizoaffective disorderArch Gen Psychiatry199956324124710078501
   PubMed Web of Science ®Google Scholar
• SwartzMSStroupTSMcEvoyJPWhat CATIE found: results from the schizophrenia trialPsychiatr Serv200859550050618451005
   PubMed Web of Science ®Google Scholar
• PousaEOchoaSCoboJA deeper view of insight in schizophrenia: insight dimensions, unawareness and misattribution of particular symptoms and its relation with psychopathological factorsSchizophr Res2017189616828237605
   PubMed Web of Science ®Google Scholar
• KeithSJPaniLNickBPractical application of pharmacotherapy with long-acting risperidone for patients with schizophreniaPsychiatr Serv2004559997100515345759
   PubMed Web of Science ®Google Scholar
• EmsleyRChilizaBAsmalLMashileMFusar-PoliPLong-acting injectable antipsychotics in early psychosis: a literature reviewEarly Interv Psychiatry20137324725423342964
   PubMed Web of Science ®Google Scholar
• JiangYNiWHealth care utilization and treatment persistence associated with oral paliperidone and lurasidone in schizophrenia treatmentJ Manag Care Spec Pharm201521978079226308225
   PubMed Web of Science ®Google Scholar
• Corena-McLeodMComparative pharmacology of risperidone and paliperidoneDrugs R D201515216317425943458
   PubMed Web of Science ®Google Scholar
• Invega Sustenna^® [Product Monograph]Markham, ONJanssen-Ortho Inc2010
   Google Scholar
• de LeonJWynnGSandsonNBThe pharmacokinetics of paliperidone versus risperidonePsychosomatics2010511808820118446
   PubMed Web of Science ®Google Scholar
• CletonARossenuSCrauwelsHA single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophreniaJ Clin Pharmacol20145491048105724676998
   PubMed Web of Science ®Google Scholar
• KramerMLitmanRHoughDPaliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety studyInt J Neuropsychopharmacol201013563564719941696
   PubMed Web of Science ®Google Scholar
• NasrallahHAGopalSGassmann-MayerCA controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophreniaNeuropsychopharmacology201035102072208220555312
   PubMed Web of Science ®Google Scholar
• GopalSHoughDWXuHEfficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response studyInt Clin Psychopharmacol201025524725620389255
   PubMed Web of Science ®Google Scholar
• PandinaGJLindenmayerJPLullJA randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophreniaJ Clin Psychopharmacol201030323524420473057
   PubMed Web of Science ®Google Scholar
• AlphsLBossieCASliwaJKMaYWTurnerNOnset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trialAnn Gen Psychiatry20111011221481243
   PubMed Web of Science ®Google Scholar
• HoughDGopalSVijapurkarULimPMorozovaMEerdekensMPaliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled studySchizophr Res20101162–310711719959339
   PubMed Web of Science ®Google Scholar
• GopalSVijapurkarULimPMorozovaMEerdekensMHoughDA 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophreniaJ Psychopharmacol201125568569720615933
   PubMed Web of Science ®Google Scholar
• FuDJTurkozIWallingDLindenmayerJPSchoolerNRAlphsLPaliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorderSchizophr Res Epub2017425
   Web of Science ®Google Scholar
• FleischhackerWWGopalSLaneRA randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophreniaInt J Neuropsychopharmacol201215110711821777507
   PubMed Web of Science ®Google Scholar
• PandinaGLaneRGopalSA double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophreniaProg Neuropsychopharmacol Biol Psychiatry201135121822621092748
   PubMed Web of Science ®Google Scholar
• FuDJBossieCAKernSJMaYWAlphsLPaliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimensClin Schizophr Relat Psychoses201482101109109A23446197
   PubMedGoogle Scholar
• FuDJBossieCASliwaJKMaYWAlphsLPaliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparisonInt Clin Psychopharmacol2014291455524113628
   PubMed Web of Science ®Google Scholar
• LiHRuiQNingXXuHGuNA comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophreniaProg Neuropsychopharmacol Biol Psychiatry20113541002100821315787
   PubMed Web of Science ®Google Scholar
• KoshikawaYTakekitaYKatoMThe comparative effects of risperidone long-acting injection and paliperidone palmitate on social functioning in schizophrenia: a 6-month, open-label, randomized controlled pilot trialNeuropsychobiology2016731354226812618
   PubMed Web of Science ®Google Scholar
• TakekitaYKoshikawaYFabbriCCognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trialBMC Psychiatry20161617227236412
   PubMed Web of Science ®Google Scholar
• AlphsLMaoLLynnSHBensonCA pragmatic analysis comparing once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in patients with schizophreniaSchizophr Res20161702–325926426742509
   PubMed Web of Science ®Google Scholar
• KwonJSKimSNHanJSatisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychoticsInt Clin Psychopharmacol201530632032826196188
   PubMed Web of Science ®Google Scholar
• NaberDHansenKForrayCQualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophreniaSchizophr Res20151681–249850426232241
   PubMed Web of Science ®Google Scholar
• McEvoyJPByerlyMHamerRMEffectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trialJAMA2014311191978198724846035
   PubMed Web of Science ®Google Scholar
• RosenheckRALeslieDLSintKJCost-effectiveness of long-acting injectable paliperidone palmitate versus haloperidol decanoate in maintenance treatment of schizophreniaPsychiatr Serv201667101124113027247177
   PubMed Web of Science ®Google Scholar
• SchreinerAAadamsooKAltamuraACPaliperidone palmitate versus oral antipsychotics in recently diagnosed schizophreniaSchizophr Res20151691–339339926431793
   PubMed Web of Science ®Google Scholar
• GopalSXuHMcQuarrieKCaregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studiesNPJ Schizophr2017312328751663
   PubMed Web of Science ®Google Scholar
• AttardAOlofinjanaOCorneliusVCurtisVTaylorDPaliperidone palmitate long-acting injection – prospective year-long follow-up of use in clinical practiceActa Psychiatr Scand20141301465124117209
   PubMed Web of Science ®Google Scholar
• HargarterLLahayeMCherubinPTreatment response and tolerability with once-monthly paliperidone palmitate initiated shortly after hospital admission in patients with schizophreniaWorld J Biol Psychiatry Epub201768
   Web of Science ®Google Scholar
• BaserOXieLPesaJDurkinMHealthcare utilization and costs of veterans health administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychoticsJ Med Econ201518535736525525771
   PubMed Web of Science ®Google Scholar
• BressingtonDStockJHulbertSMacInnesDA retrospective observational study of the effectiveness of paliperidone palmitate on acute inpatient hospitalization ratesInt Clin Psychopharmacol201530423023625882381
   PubMed Web of Science ®Google Scholar
• DoshiJAPettitARStoddardJJZummoJMarcusSCConcurrent oral antipsychotic drug use among schizophrenia patients initiated on long-acting injectable antipsychotics post-hospital dischargeJ Clin Psychopharmacol201535444244626075492
   PubMed Web of Science ®Google Scholar
• SchreinerABergmansPCherubinPA prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agentsClin Ther201436101372138825444566
   PubMed Web of Science ®Google Scholar
• SchreinerABergmansPCherubinPPaliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychoticsJ Psychopharmacol201529891092225999398
   PubMed Web of Science ®Google Scholar
• HargarterLCherubinPBergmansPIntramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychoticsProg Neuropsychopharmacol Biol Psychiatry2015581725448776
   PubMed Web of Science ®Google Scholar
• ZhaoJLiLShiJSafety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV studyNeuropsychiatr Dis Treat2017132045205628814873
   PubMed Web of Science ®Google Scholar
• LafeuilleMHGrittnerAMFortierJComparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychoticsAm J Health Syst Pharm201572537838925694413
   PubMed Web of Science ®Google Scholar
• MontalvoIOrtegaLLopezXChanges in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitateInt Clin Psychopharmacol2013281464923232756
   PubMed Web of Science ®Google Scholar
• MorratoEHParksJCampagnaEJComparative effectiveness of injectable paliperidone palmitate versus oral atypical antipsychotics: early postmarketing evidenceJ Comp Eff Res201542899925251693
   PubMed Web of Science ®Google Scholar
• TaylorDOlofinjanaOLong-acting paliperidone palmitate – interim results of an observational study of its effect on hospitalizationInt Clin Psychopharmacol201429422923424419004
   PubMed Web of Science ®Google Scholar
• TaylorDMSparshattAO’HaganMDzahiniOPaliperidone palmitate: factors predicting continuation with treatment at 2 yearsEur Neuropsychopharmacol201626122011201727743760
   PubMed Web of Science ®Google Scholar
• TaylorDMSparshattAO’HaganMDzahiniOEffect of paliperidone palmitate on hospitalisation in a naturalistic cohort – a four-year mirror image studyEur Psychiatry201637434827447102
   PubMed Web of Science ®Google Scholar
• VossEARyanPBStangPEHoughDAlphsLSwitching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims databaseInt Clin Psychopharmacol201530315115725730525
   PubMed Web of Science ®Google Scholar
• WhaleRPereiraMCuthbertSFialhoREffectiveness and predictors of continuation of paliperidone palmitate long-acting injection treatment: a 12-month naturalistic cohort studyJ Clin Psychopharmacol201535559159526267419
   PubMed Web of Science ®Google Scholar
• ZhangFSiTChiouCFEfficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophreniaNeuropsychiatr Dis Treat20151165766825792835
   PubMed Web of Science ®Google Scholar
• PesaJADoshiDWangLYuceHBaserOHealth care resource utilization and costs of California Medicaid patients with schizophrenia treated with paliperidone palmitate once monthly or atypical oral antipsychotic treatmentCurr Med Res Opin201733472373128044455
   PubMed Web of Science ®Google Scholar
• PilonDMuserELefebvrePKamstraREmondBJoshiKAdherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophreniaBMC Psychiatry201717120728576133
   PubMed Web of Science ®Google Scholar
• EmsleyRHargarterLBergmansPOnce-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophreniaNeuropsychiatr Dis Treat2017132261226928919757
   PubMed Web of Science ®Google Scholar
• CarpinielloBPinnaFCritical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophreniaDrug Des Devel Ther20161017311742
   PubMed Web of Science ®Google Scholar
• BerwaertsJLiuYGopalSEfficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trialJAMA Psychiatry201572883083925820612
   PubMed Web of Science ®Google Scholar
• SavitzAJXuHGopalSEfficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority studyInt J Neuropsychopharmacol2016197
   PubMed Web of Science ®Google Scholar
• SavitzAJXuHGopalSNuamahIHoughDMathewsMPaliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and noninferiority studyInt Clin Psychopharmacol201732632933628806194
   PubMed Web of Science ®Google Scholar
• SavitzAJXuHGopalSEfficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority studyNeuropsychiatr Dis Treat2017132193220728860777
   PubMed Web of Science ®Google Scholar
• LambYNKeatingGMPaliperidone palmitate intramuscular 3-monthly formulation: a review in schizophreniaDrugs201676161559156627699643
   PubMed Web of Science ®Google Scholar
• WeidenPJKimEBermakJTurkozIGopalSBerwaertsJDoes half-life matter after antipsychotic discontinuation? A relapse comparison in schizophrenia with 3 different formulations of paliperidoneJ Clin Psychiatry2017787e813e82028640988
   PubMed Web of Science ®Google Scholar